



# Antithrombotic Reversal – Adult – Inpatient Clinical Practice Guideline

*Note: Active Table of Contents – Click to follow link*

<b>EXECUTIVE SUMMARY</b> .....	<b>3</b>
<b>SCOPE</b> .....	<b>4</b>
<b>METHODOLOGY</b> .....	<b>4</b>
<b>DEFINITIONS</b> .....	<b>5</b>
<b>INTRODUCTION</b> .....	<b>5</b>
<b>RECOMMENDATIONS</b> .....	<b>5</b>
<b>UW HEALTH IMPLEMENTATION</b> .....	<b>15</b>
<b>APPENDIX A. EVIDENCE GRADING SCHEME(S)</b> .....	<b>16</b>
<b>REFERENCES</b> .....	<b>21</b>

**Contact for Content:**

Name: Anne Rose, PharmD – Pharmacy Department

Phone Number: (608) 263-9738

Email Address: [ARose@uwhealth.org](mailto:ARose@uwhealth.org)

**CPG Contact for Changes:**

Name: Philip Trapskin, PharmD, BCPS, Director of Drug Policy

Phone Number: (608) 265-0341

Email Address: [PTrapskin@uwhealth.org](mailto:PTrapskin@uwhealth.org)

**Guideline Author(s):**

Anne Rose, PharmD – Anticoagulation Stewardship Program

**Coordinating Team Members:**

John Hoch, MD – Department of Surgery – Vascular

Kraig Kumfer, MD, PhD – Hospital Medicine

Joshua Medow, MD – Neurological Surgery

John Sheehan, MD – Hematology

Eliot Williams, MD - Hematology

**Review Individuals/Bodies:**

Donna Lawler – Special Anticoag Lab

**Committee Approvals/Dates:**

Inpatient Anticoagulation Committee (Last Periodic Review: 09/11/17)

Pharmacy & Therapeutics Committee (Last Periodic Review: 11/2017)

**Release Date:** October 2017 | **Next Review Date:** October 2019

Original Release 2013

## **Executive Summary**

### **Guideline Overview**

The intent of this guideline is to provide evidence-based recommendations for the treatment of bleeding in patients on antithrombotic therapy and standardize care within UW Health. The guideline provides reversal recommendations for the following: warfarin, oral and intravenous direct thrombin inhibitors, oral anti-Xa inhibitors, heparin-based medications, fondaparinux, NSAIDs, P2Y12 ASP receptor inhibitors, phosphodiesterase inhibitors and glycoprotein IIb/IIIa inhibitors. Procoagulant agent use includes desmopressin, plasma (commonly referred to as FFP), factor 7A, idarucizumab, prothrombin complex concentrate (PCC), phytonadione, and protamine.

### **Key Revisions (2017 Periodic Review)**

List any MAJOR revisions which were made between full periodic reviews or during last review.

1. Addition of low, fixed dose prothrombin complex concentrate for warfarin reversal
2. Addition of reversal recommendations for antiplatelet agents

### **Key Practice Recommendations**

To quickly view reversal recommendations for specific antithrombotic medications select hyperlink below.

1. [Warfarin and Prothrombin Complex Concentrate \(PCC\)](#)
2. [Dabigatran](#)
3. [Anti-Xa: Apixaban, Rivaroxaban, Edoxaban](#)
4. [Heparin and Low Molecular Weight Heparin](#)
5. [Direct Thrombin Inhibitors: Argatroban and Bivalirudin](#)
6. [Fondaparinux](#)
7. [Aspirin](#)
8. [Non-steroidal Anti-inflammatory Drugs \(NSAIDs\)](#)
9. [P2Y12 ADP Receptor Inhibitors \(clopidogrel, prasugrel, ticagrelor\)](#)
10. [Phosphodiesterase Inhibitor \(cilostazol\)](#)
11. [Glycoprotein IIb/IIIa inhibitor \(eptifibatide, abciximab\)](#)

### **Companion Documents**

1. [Appendix A GRADE Methodology Evidence Grading Scheme](#)
2. [Appendix B Treatment of Bleeding Associated with Oral Anticoagulants](#)
3. [Appendix C Treatment of Bleeding Associated with Parenteral Anticoagulants](#)
4. [Appendix D Treatment of Life Threatening Bleeding Associated with Anticoagulants](#)
5. [Appendix E Administration Rate of Intravenous Procoagulant Agents](#)
6. [Appendix F Literature Summary for Low Fixed Dose PCC](#)
7. [UW Health Warfarin Management - Adult - Ambulatory - Clinical Practice Guideline](#)
8. [UW Health Warfarin Management - Adult - Inpatient Clinical Practice Guideline](#)
9. [UW Health Heparin- Induced Thrombocytopenia – Adult – Inpatient Clinical Practice Guideline](#)
10. [UW Health Unfractionated Heparin \(Therapeutic Dosing\) - Adult - Inpatient Clinical Practice Guideline](#)
11. [UW Health Antithrombotics in Non-Valvular Atrial Fibrillation - Adult - Inpatient/Ambulatory Clinical Practice Guideline](#)
12. [UW Health Indications for Blood Product Transfusion – Adult – Inpatient/Ambulatory Clinical Practice Guideline](#)

### 13. [UW Health IV Administration Guideline – Adult – Inpatient/Ambulatory Clinical Practice Guideline](#)

#### **Scope**

**Disease/Condition(s):** Treatment of adult non-hemophiliac bleeding or with high potential for bleeding (i.e. intra-operatively) due to antithrombotic therapy at UW Health.

**Clinical Specialty:** Neurology, Trauma, Critical Care, Cardiology, Surgery, Emergency, Nursing, Pharmacy

**Intended Users:** Physicians, mid-level providers, pharmacists, nurses, students

**Objective(s):** Provide evidence-based recommendations for the treatment of bleeding in patients on antithrombotic therapy and standardize care within UW Health.

**Target Population:** Adult inpatient and emergency department patients

**Interventions and Practices Considered:** Procoagulant agent use includes desmopressin, plasma (commonly referred to as FFP), factor 7A, idarucizumab, prothrombin complex concentrate (PCC), phytonadione, and protamine.

**Major Outcomes Considered:** Control of bleeding, improved neurological, cardiac, and renal outcomes. Thromboembolic events post reversal.

#### **Methodology**

##### **Methods Used to Collect/Select the Evidence:**

Electronic database searches (e.g., PUBMED) were conducted by the guideline author(s) and workgroup members to collect evidence for review. Expert opinion and clinical experience were also considered during discussions of the evidence.

##### **Methods Used to Formulate the Recommendations:**

The workgroup members agreed to adopt recommendations developed by external organizations and/or arrived at a consensus through discussion of the literature and expert experience. All recommendations endorsed or developed by the guideline workgroup were reviewed and approved by other stakeholders or committees (as appropriate).

##### **Methods Used to Assess the Quality of the Evidence/Strength of the Recommendations:**

Recommendations developed by external organizations maintained the evidence grade assigned within the original source document and were adopted for use at UW Health.

Internally developed recommendations, or those adopted from external sources without an assigned evidence grade, were evaluated by the guideline workgroup using an algorithm adapted from the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (see **Figure 1** in [Appendix A](#)).

##### **Rating Scheme for the Strength of the Evidence/Recommendations:**

See [Appendix A](#) for the rating scheme(s) used within this document.

## **Definitions**<sup>1</sup>

1. Minor bleed – epistaxis lasting less than 1 hour, small amount of blood in stool, urine or oral cavity.
2. Non- major bleeding – bleeding with decline in Hgb of <2 g/dL or requiring ≤ 1 unit of blood or packed cells.
3. Major bleed - Acute major bleeding that includes one of the following: potentially life-threatening, acute Hgb decline of ≥ 2 g/dL or acute bleeding requiring at least two units of blood or packed cells (International Society on Thrombosis and Haemostasis).
4. Life-threatening bleed – fatal bleeding, symptomatic intracranial bleeding, reduction in hemoglobin of at least 5 g/dL, transfusion of at least 4 units of blood or packed cells, bleeding associated with hypotension requiring use of intravenous inotropic agents, bleeding necessitating surgical intervention (International Society on Thrombosis and Haemostasis).
5. Massive trauma bleeding – loss of complete blood volume (approximately 0.7 L/kg lean body weight) within 24 hours or half of blood volume within three hours.

## **Introduction**

Bleeding is a major complication for any type of anticoagulant therapy and can result in a chronic debilitating condition or death.<sup>2-5</sup> The risk of hemorrhage is often associated with the intensity of anticoagulation.<sup>6</sup> Another consideration is the increased risk of bleeding with concomitant treatment such as antiplatelet medication, non-steroidal anti-inflammatory agents and cyclooxygenase type-2 inhibitors. Depending on the antithrombotic agent and its half-life, the duration of action can vary from a few hours to several days. When bleeding is life-threatening or when urgent reversal is required prior to surgery, there may be the need for reversal. . The risk of bleeding versus thromboembolism must be evaluated for each specific patient. The optimal approach must take into account patient comorbidities, extent of anticoagulation and target level of anticoagulation after reversal. Treatment goals include cessation of bleeding while minimizing the risk of untoward thrombosis with improvement in clinical outcome.

Inherent limitations in non-randomized, non-comparator trials must be considered while examining the evidence. Over time, natural hemostasis is expected in hemorrhagic injury. Thus non-randomized, non-comparator case studies reporting reduction or cessation of bleeding after administration of procoagulants must be interpreted with caution, as the influence of time cannot be assessed without a comparator, and the true influence of the administered reversal agent cannot be accurately assessed.

## **Recommendations**

**Oral Anticoagulants:** *Listed by drug class*

### **Vitamin K Antagonist (i.e. Warfarin)**

Warfarin inhibits the activation of vitamin K dependent clotting factors II, VII, IX and X by inhibiting two specific enzymes, vitamin K epoxide reductase (VKOR) and vitamin K<sub>1</sub> reductase, and blocking the production of pharmacologically active vitamin K clotting factors. The incidence of hemorrhagic events associated with warfarin therapy is based on target INR, duration of therapy, use on concomitant antiplatelet therapy, patient factors, and quality of monitoring.<sup>6-8</sup>

Patient factors such as prior history of bleeding, advanced age, cancer, renal or hepatic insufficiency, arterial hypertension, prior stroke and alcohol abuse are associated with a higher risk of hemorrhage.<sup>6,9-11</sup> The rate of hemorrhage increases markedly in patients with an INR

greater than 4.5.<sup>12</sup> Bleeding or potential bleeding of patients on warfarin can be managed by holding warfarin doses, administering phytonadione, plasma and/or PCC. The approach to treatment is predicated on the indication for warfarin, location of the bleed, extent of bleeding and INR ([Appendix B](#)).<sup>2</sup> For further information on warfarin treatment, see [UW Health Warfarin Management - Adult - Ambulatory - Clinical Practice Guideline](#) or [UW Health Warfarin Management - Adult - Inpatient Clinical Practice Guideline](#).

1. The INR and either the extent of bleeding or timing of surgical intervention should be used to determine the level of warfarin reversal.<sup>2</sup> Table 2 provides common clinical scenarios and reversal options. (*UW Health high quality of evidence, strong recommendation*)



Table 2. Considerations for Warfarin Reversal Based on Clinical Scenario

Clinical Scenario	Reversal Strategy	Recheck INR	Other Considerations
INR 4.5 – 9.9 with NO significant bleeding	Omit 1-2 doses of warfarin	24–48 hours	For high INR no difference in incidence of bleeding was seen between patients treated with phytonadione versus placebo <sup>7</sup>
INR > 9.9 with NO significant bleeding	Omit warfarin until INR is near or within target range  Phytonadione 1 – 2.5 mg orally (preferred) or IV	24 hours	
Any INR with non-major bleeding	Omit 1-2 doses of warfarin <i>May consider:</i> <i>Phytonadione 1 - 5 mg orally (preferred) or IV</i>	24–48 hours	Dose phytonadione based on INR, risk of thrombosis, and extent of bleeding
Any INR with major or life threatening bleeding	Stop warfarin until bleeding controlled  Phytonadione 5-10 mg IV <b>AND</b> PCC dose based on INR	30 mins after PCC dose	Administer each agent as soon as it is available.  There is no specific order of administration <sup>13</sup>
Any INR with need for reversal for planned procedure (> 24 hours)	Omit warfarin  <i>May consider based on timing:</i> <i>Phytonadione 5 mg IV</i>	12 hours	If INR remains elevated then may consider repeating phytonadione dose or checking INR prior to surgery
Any INR with need for reversal for emergent surgery (< 24 hours)	Stop warfarin until safe to resume post-operatively  PCC dose based on INR  <i>May consider:</i> <i>Phytonadione 5-10 mg IV if not planning to resume warfarin immediately post-operatively</i>	30 mins after PCC dose	If expected length of surgery > 6 hours, phytonadione should be administered with PCC

2. It is reasonable to administer PCC (at dosing listed in Table 3) with or without phytonadione for patients requiring warfarin reversal prior to emergency surgery or major invasive procedures.<sup>14,15</sup> (*UW Health moderate level of evidence, weak/conditional recommendation*)
  - 2.1. There is data to support the use of low fixed dosed PCC for warfarin reversal. See [Appendix F](#) for literature summary. In the literature the majority of patients achieved the targeted INR goal after low dose PCC was administered without the need for supplemental PCC dosing. Failure to hit target INR goals were more commonly seen when the INR was > 6.0.<sup>16-23</sup> (*UW Health moderate level of evidence, weak/conditional recommendation*)
  - 2.2. If a patient is HIT positive, but more than 3 months ago, PCC can be administered (despite heparin content in PCC). If HIT was diagnosed less than 3 months ago evaluate benefit of procoagulant use versus risk of repeat HIT.<sup>24</sup> (*UW Health very low level of evidence, weak/conditional recommendation*)

Table 3. Prothrombin Complex Concentrate Dosing for Warfarin Reversal<sup>16-23</sup> (*UW Health moderate level of evidence, weak/conditional recommendation*)

Pre-Treatment INR	Dose of PCC	Recheck INR
< 6.0	1000 units	15 – 30 mins after dose
≥ 6.1	2000 units	15 – 30 mins after dose
Any INR with CNS bleed	2000 units	15 – 30 mins after dose
May repeat with 500 units if INR goal or clinical outcome is not achieved		

3. Routine use of FFP for reversal of INR or warfarin-related hemorrhage should be limited. (*UW Health low level of evidence, weak/conditional recommendation*)
  - 3.1. Studies have shown FFP fails to consistently reach the target INR goal when compared to PCC for INR reversal.<sup>25-29</sup>
  - 3.2. FFP is associated with higher fluid volumes per dose and transfusion related acute lung injury (TRALI)<sup>30</sup>
  - 3.3. FFP may be used for emergent partial INR reversal (i.e. INR goal ≤ 2) or when large volumes of blood are being replaced.<sup>31</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
4. Routine use of Factor 7A for reversal of warfarin-related hemorrhage is not recommended.<sup>32-34</sup> (*UW Health high level of evidence, strong recommendation*)

#### **Direct Thrombin Inhibitor (i.e. Dabigatran)**

Dabigatran is a reversible, oral direct thrombin inhibitor and an association between dose and incidence of bleeding is established in patients with atrial fibrillation.<sup>35</sup> Unlike warfarin, anticoagulation occurs through inhibition of factor II (thrombin), not depletion of the clotting factors. The half-life is 12 to 17 hours (in patients with normal renal function) and within 24 hours of stopping dabigatran, concentrations are reduced by approximately 75% of the original concentration in patients with normal renal function. Due to the short duration of effect, discontinuation of dabigatran could be sufficient to mitigate anticoagulant effects.<sup>2,36</sup>

1. The time of last dose, renal function, and either the extent of bleeding or time to surgical intervention should be used to determine the level of reversal needed. Table 4 provides common clinical scenarios and reversal options. (*UW Health moderate level of evidence, weak/conditional recommendation*)



Table 4. Considerations for Dabigatran Reversal Based on Clinical Scenario<sup>37-39</sup> (UW Health moderate level of evidence, weak/conditional recommendation)

Clinical Scenario	Reversal Strategy	Lab Monitoring	Other Considerations
Minor or non-clinically relevant bleeding	Hold dabigatran	N/A	Within 24 hours of stopping, dabigatran concentrations are reduced by 75% in normal renal function
Major or Life Threatening Bleeding	Hold dabigatran  If dose taken $\leq$ 12 hrs (normal renal function): Idarucizumab  If dose taken $>$ 12 hrs, if last dose unknown or renal insufficiency then check TT: <ul style="list-style-type: none"> <li>• If TT <math>\geq</math> 25 secs: Idarucizumab</li> <li>• If TT <math>&lt;</math> 25 secs: no reversal needed</li> </ul>	Creatinine  Thrombin Time (TT)	
Planned Surgery	Hold dabigatran <a href="#">UW Health Perioperative and Regional Anesthesia Management with Antithrombotic Therapy – Adult – Inpatient/Ambulatory Clinical Practice Guideline</a>	Creatinine (at least 7 days prior)	
Emergent Surgery	Hold dabigatran  If dose taken $\leq$ 12 hrs (normal renal function): Idarucizumab  If dose taken $>$ 12 hrs, if last dose unknown or renal insufficiency then check TT: <ul style="list-style-type: none"> <li>• If TT <math>\geq</math> 25 secs: Idarucizumab</li> <li>• If TT <math>&lt;</math> 25 secs: no reversal needed</li> </ul>	Creatinine  Thrombin Time (TT)	

### Anti-Xa Inhibitors (i.e. apixaban, edoxaban, rivaroxaban)

With oral factor Xa inhibitors, unlike warfarin, anticoagulation occurs through inhibition of factor Xa, not inhibition of production of clotting factors. No direct reversal agent is available. Apixaban, edoxaban, and rivaroxaban have relatively short half-lives in patients with normal renal function (apixaban 12 hours, rivaroxaban 5- 9 hours, edoxaban 10-14 hours). The anticoagulant effect of these agents is minimal in patients 48 hours after ingestion<sup>40-42</sup> The benefit of coagulation must be weighed with the risk of thrombosis based on time of last dose, comorbidities, and patient characteristics.

There is data from cross over studies, utilizing healthy volunteers that suggest PCC is effective in correcting anticoagulation laboratory values. Dosing of PCC in these studies used 25 – 50 units/kg/dose.<sup>43-46</sup> While promising the major limitation to these studies is application to clinical bleeding outcomes. Limited data exists for use of PCC in bleeding caused by Xa inhibitors.

Case reports and retrospective reviews show PCC to be effective in managing bleeding in 33-69% of patients treated. Failure to achieve hemostasis was more commonly seen in ICH.<sup>47-52</sup>

Factor 7A was also evaluated in the *ex vivo* study of healthy volunteers receiving one dose of rivaroxaban 20 mg and decreased time to reach the maximum concentration of thrombin, but did not increase thrombin generation potential to the same extent as PCC.<sup>44</sup> There are no data to recommend for or against use of factor 7A for the treatment of life-threatening bleeding associated with factor Xa inhibitors.

1. For minor or non-clinically significant bleeding hold Xa inhibitor until bleeding subsides and it is deemed safe to resume anticoagulation. For planned surgical procedures hold Xa inhibitor per [UW Health Perioperative and Regional Anesthesia Management with Antithrombotic Therapy – Adult – Inpatient/Ambulatory Clinical Practice Guideline](#) recommendations. (*UW Health moderate level of evidence, strong recommendation*)
2. For major or life-threatening bleeding or the need for emergent surgery PCC may be considered.<sup>43-52</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
  - 2.1 Optimum dosing of PCC is unknown; however, doses of 25 – 50 Units/kg (maximum 5000 units) might be considered<sup>43-52</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

### **Parenteral Anticoagulants:** *Listed by drug class*

#### **Heparinoids (i.e. unfractionated heparin, low molecular weight heparin)**

Unfractionated heparin (UFH) binds to anti-thrombin III to enhance the rate of neutralization of factors II (thrombin) and Xa. Therapeutic doses neutralize thrombin and thereby prevent the conversion of fibrinogen to fibrin.<sup>53</sup> The half-life is only 60 to 90 minutes therefore; therapeutic effect is eliminated within three to four hours.

Similar to UFH, the primary anticoagulant activity of low molecular weight heparin (LMWH) (i.e., enoxaparin, dalteparin) is through antithrombin inhibition of coagulation factors. However, LMWH binds to factor Xa to a greater extent than thrombin and exhibits a more predictable dose response than unfractionated heparin.<sup>53</sup> The risk of bleeding from LMWH correlates with the extent of anticoagulation, but no established method for total reversal of anticoagulation from LMWH exists. Protamine will only neutralize thrombin activity and has limited, if any activity, on anti-factor Xa activity.<sup>54-56</sup>

1. The dose, time of last dose and renal function should be used to determine the dose of protamine needed for reversal. Table 5 provides reversal strategies for UFH and LMWH. (*UW Health high level of evidence, strong recommendation*)

Table 5. Considerations for Protamine in UFH or LMWH Reversal<sup>53, 57-59</sup> (*UW Health high level of evidence, strong recommendation*)

Drug	Reversal Strategy	Monitoring	Other Considerations
UFH	Protamine 1 mg per 100 units of heparin administered within last 2 hours (Max dose 50 mg) <sup>61</sup>	Anti-Xa aPTT ACT	
LMWH	If given in last 8 hrs: Protamine 1 mg per 100 anti-Xa units (1 mg) of LMWH (Max 50 mg) <sup>39,111</sup>  If given > 8 hr but < 12 hr: Protamine 0.5 mg per 100 anti-Xa units (1 mg) of LMWH <sup>61</sup>	Anti-Xa	In renal insufficiency may consider protamine use beyond 12 hours  May consider redosing if bleeding persists 0.5 mg per 1 mg (max 25 mg)

Insufficient evidence exists to make recommendations for or against the use of Factor 7A in patients with life-threatening bleeding unresponsive to other therapies. Factor 7A 40mcg/kg may facilitate bleeding control in patients treated with LMWH.<sup>60</sup> Case reports of life-threatening bleeding in patients treated with LMWH utilized factor 7A 20-120 mcg/kg to reverse bleeding.<sup>11861-63</sup>

### Direct Thrombin Inhibitors (i.e argatroban, bivalirudin)

Argatroban and bivalirudin are parenteral direct thrombin inhibitors.<sup>64,65</sup> There are no established reversal agents; however the short half-lives (argatroban 45 minutes; bivalirudin 25 minutes) result in a short duration of anticoagulation action often precluding the need for additional procoagulant therapy.<sup>53</sup>

Factor 7A has theoretical applications in reversing argatroban-associated hemorrhage, though clinical experience for off-label use is limited and has not demonstrated benefit.<sup>66,67</sup> Although a report demonstrates factor 7A could overcome argatroban anticoagulation based on normal thromboelastography, this does not represent recovery of thrombin generation and normalized coagulation.<sup>68,69</sup> One case report of an infant receiving argatroban failed to demonstrate hemostasis with factor 7A.<sup>66</sup> Insufficient evidence exists to make recommendations for or against the use of factor 7A for the treatment of life-threatening bleeding with argatroban.

1. Use supportive measures to control bleeding. Insufficient evidence exists to recommend factor 7A use in argatroban or bivalirudin related hemorrhage.<sup>66-69</sup> (*UW Health very low level of evidence, weak/conditional recommendation*)

### Anti-Xa Inhibitor (i.e. fondaparinux)

**Fondaparinux** is a factor Xa inhibitor with an elimination half-life of 17–21 hours.<sup>70</sup> There is no established reversal agent for fondaparinux.<sup>53</sup>

There is insufficient evidence to recommend for or against treatment of major or life-threatening bleeding due to fondaparinux with factor 7A.<sup>53,59,69</sup> No clinical trial is available to demonstrate improved clinical outcomes in patients treated with factor 7A; only case reports are available. In 16 healthy male subjects weighing less than 100 kg treated with 10 mg of fondaparinux, a single dose of factor 7A 90 mcg/kg reduced the thrombin generation time, activated partial

thromboplastin time, and prothrombin time, and increased the endogenous thrombin potential within 1.5 hours of administration.<sup>71</sup> Young and colleagues again demonstrated in-vitro reversal of fondaparinux-induced anticoagulation with factor 7A using concentrations the authors anticipate would be achieved with factor 7A dosing of 90-270 mcg/kg.<sup>68</sup> Reversal of clinically-significant bleeding from fondaparinux has not been clearly demonstrated with factor 7A, though a case report notes management of fondaparinux-associated intracerebral hemorrhage with factor 7A administration (90 mcg/kg x 1) and neurosurgical evacuation.<sup>59</sup> The authors indicated hemostasis was achieved; however, the patient did not survive.

1. For major or life-threatening bleeding factor 7A may be considered.<sup>59,68,71</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
2. Protamine is not effective for the treatment of bleeding associated with fondaparinux.<sup>53</sup> (*UW Health low level of evidence, strong recommendation*)

### **Antiplatelets**

There are several classes of antiplatelet agents available: cyclo-oxygenase inhibitors (COX-inhibitors): i.e. aspirin, ibuprofen, naproxen; P2Y<sub>12</sub> ADP receptor inhibitors (i.e. clopidogrel, prasugrel, ticagrelor, ticlopidine); phosphodiesterase inhibitor (i.e. cilostazol) and glycoprotein IIb/IIIa inhibitors (i.e. eptifibatide, abciximab). Antiplatelets associated with a higher level of platelet inhibition are suspected to cause higher incidence of ICH, ICH volume growth, need for craniotomy and mortality. There is no specific antidote for antiplatelet agents. In general, platelet function is restored after 3-5 half-lives of a reversible antiplatelet and not until new platelets are regenerated for irreversible antiplatelets. This can influence the approach to antiplatelet reversal.<sup>72-74</sup> For recommendations on reversal for planned procedures see: [UW Health Periprocedural and Regional Anesthesia Management with Antithrombotic Therapy – Adult – Inpatient/Ambulatory Clinical Practice Guideline.](#)

When considering reversal options for antiplatelet agents it is important to consider the severity of bleeding and if it demonstrates reversible or irreversible antiplatelet effect. General recommendations for antiplatelets include<sup>72,75</sup>:

1. Reversal of antiplatelets is usually only recommended in life threatening bleeding (i.e. intracranial hemorrhage). (*UW Health moderate level of evidence, strong recommendation*)
2. Supportive measures should be used to help manage bleeding. (*UW Health low level of evidence, weak/conditional recommendation*)
3. Surgical procedures should be delayed, when possible but if emergent surgery is needed then supportive measures intraoperatively can be used for managing bleeding (*UW Health low level of evidence, weak/conditional recommendation*)

### **Cyclo-oxygenase inhibitor (COX-inhibitors): i.e. aspirin, ibuprofen, naproxen**

Non-selective cox-inhibitors prevent the conversion of arachidonic acid to thromboxane A<sub>2</sub>, thus inhibiting platelet activation and aggregation. Aspirin causes irreversible inhibition of platelet aggregation. The effect of aspirin can last 5-7 days after discontinuation. Other non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX with a reversible dose dependent effect. As the drug concentration decreases, COX activity returns. The effect is dependent on the elimination half-life of each drug.<sup>72,76</sup>

## Aspirin

There is some data to suggest platelet transfusion can be used in patients with intracranial hemorrhage undergoing craniotomy. In one randomized, controlled trial, patients who received platelet transfusion experienced less intraparenchymal hemorrhage recurrence, lower post-operative hematoma volume, and decreased mortality.<sup>77</sup>

The PATCH trial studied platelet transfusion for intracerebral hemorrhage associated with antiplatelet use. All antiplatelets were included, but COX inhibitor monotherapy represented the largest antiplatelet therapy in both groups (73% in transfusion and 84% standard care). Patients who underwent surgical evacuation within 24 hours of admission were excluded. The results showed platelet transfusions associated with worsening outcomes regarding functional status and death and no change in volume growth.<sup>78</sup>

1. Intracranial hemorrhage undergoing surgical evacuation (i.e. craniotomy) platelet transfusion may be considered<sup>72,77,78</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
  - 1.1. Allow 3-5 half lives of the implicated antiplatelet agent to elapse before attempting to infuse platelets. This will minimize pharmacologic inhibition of the transfused platelets.<sup>72</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
2. Intracranial hemorrhage without surgical evacuation platelet transfusion is not recommended.<sup>72,77,78</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

While not well studied, desmopressin (DDAVP) may be considered. A single dose of DDAVP was used in patients on aspirin undergoing CABG. The DDAVP group resulted in less chest tube output and total blood loss but no difference in transfusion requirements.<sup>79</sup> Another study used two doses of DDVAP in open cholecystectomy. It demonstrated shortened bleeding time when compared to placebo.<sup>80</sup> Another study in intracranial hemorrhage showed platelet stabilization through platelet function measurements with a single dose, although effect only lasted 3 hours.<sup>81</sup>

3. Intracranial hemorrhage may consider DDAVP 0.4 mcg/kg<sup>72,79-81</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
  - 3.1. DDAVP can be used in addition to platelet transfusion<sup>72</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

## NSAIDs (i.e. ibuprofen, naproxen)

Due to the reversible platelet inhibition and short half-life of most NSAIDs, there is not an established role for using specific reversal agents.<sup>72</sup>

1. Use supportive measures to control bleeding. Insufficient evidence exists to recommend platelet transfusion or DDVAP to treat related hemorrhage.<sup>72</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

## P2Y12 ADP Receptor Antagonists (i.e. clopidogrel, prasugrel, ticagrelor, ticlopidine)

Platelet inhibition occurs by binding to the adenosine diphosphate (ADP) receptor on platelets and preventing activation. This inhibition is irreversible and the effect is present until the drug is eliminated and new platelets are generated.<sup>82,83</sup> The exception is with ticagrelor which reversibly inhibits platelet action.<sup>82</sup>

The use of platelet transfusion for reversal remains controversial. A single-center prospective, observational study with IPH and decreased platelet function due either to aspirin or clopidogrel. Platelet transfusion was associated with smaller hemorrhage size, however, there was no control group and different transfusion doses were given. Other studies have failed to show benefit in mortality, hemorrhage growth, or patient functionality from platelet transfusion.<sup>84-86</sup>

The PATCH trial studied platelet transfusion for intracerebral hemorrhage associated with antiplatelet use. All antiplatelets were included, but use of ADP inhibitor either as monotherapy or combination therapy with a COX inhibitor was not well represented (<4% in both comparator groups). Patients who underwent surgical evacuation within 24 hours of admission were excluded. The results showed platelet transfusions associated with worsening outcomes regarding functional status and death and no change in volume growth.<sup>78</sup>

1. Intracranial hemorrhage undergoing surgical evacuation (i.e. craniotomy) platelet transfusion may be considered<sup>78,84-86</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
  - 1.1. Allow 3-5 half lives of the implicated antiplatelet agent to elapse before attempting to infuse platelets. This will minimize pharmacologic inhibition of the transfused platelets.<sup>72</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
2. Intracranial hemorrhage without surgical evacuation platelet transfusion is not recommended.<sup>78,84-86</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

DDAVP has not been well studied to control bleeding from P2Y12 ADP inhibitors. A case report showed transient restoration of platelet function after single dose DDAVP<sup>87</sup>. In healthy subjects, DDAVP showed improvements in bleeding time and platelet function tests.<sup>88,89</sup>

3. Intracranial hemorrhage may consider DDAVP 0.4 mcg/kg<sup>72,87-89</sup> (*UW Health low level of evidence, weak/conditional recommendation*)
  - 3.2 DDAVP can be used in addition to platelet transfusion<sup>72</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

### **Phosphodiesterase Inhibitor (i.e. cilostazol)**

Phosphodiesterase inhibitors reversibly inhibit platelet aggregation. Due to the reversible platelet inhibition and relatively short half-life, there is not a role for using specific reversal agents.<sup>72</sup>

1. Use supportive measures to control bleeding. Insufficient evidence exists to recommend platelet transfusion or DDVAP to treat related hemorrhage<sup>72</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

### **Glycoprotein IIb/IIIa Inhibitors (i.e. eptifibatide, abciximab)**

Platelet inhibition occurs through the blocking of the platelet glycoprotein IIb/IIIa receptor and reversibly inhibiting platelet aggregation. Due to the short half-life of these medications, platelet function returns within 4-8 hours after discontinuation. There is no specific reversal agent available.<sup>90</sup>

1. Use supportive measures to control bleeding. Insufficient evidence exists to recommend platelet transfusion or DDVAP to treat related hemorrhage.<sup>72</sup> (*UW Health low level of evidence, weak/conditional recommendation*)

## **UW Health Implementation**

### **Potential Benefits:**

- Standardized approach to antithrombotic reversal
- Recommendations for antithrombotics where data is limited

### **Potential Harms:**

- Limited literature for some antithrombotic agents
- Risks for continued bleeding if reversal not complete
- Risks for thrombotic event after reversal

**Qualifying Statements:** Most studies evaluating procoagulant use in bleeding patients are small and/or case series or conducted in normal volunteers. Recommendations are subject to change with the publication of clinical trials and FDA approval of additional agents.

### **Pertinent UW Health Policies & Procedures**

1. Pharmacy Operating Procedure for the Emergent Use of Factor 7A (NovoSeven®)
2. Pharmacy Operating Procedure for the Emergent Use Prothrombin Complex Concentrate (PCC)

### **Patient Resources**

Not applicable

### **Guideline Metrics**

1. Metric #1: Use of appropriate agent and dosing strategy for each antithrombotic
2. Metric #2: Successful reversal
3. Metric #3: Thrombotic event post reversal


### **Implementation Plan/Clinical Tools**

1. Guideline will be posted on uConnect in a dedicated location for Clinical Practice Guidelines.
2. Release of the guideline will be advertised in the Physician/APP Briefing newsletter.
3. Content and hyperlinks within clinical tools, documents, or Health Link related to the guideline recommendations (such as the following) will be reviewed for consistency and modified as appropriate.

### **Disclaimer**

Clinical practice guidelines assist clinicians by providing a framework for the evaluation and treatment of patients. This guideline outlines the preferred approach for most patients. It is not intended to replace a clinician's judgment or to establish a protocol for all patients. It is understood that some patients will not fit the clinical condition contemplated by a guideline and that a guideline will rarely establish the only appropriate approach to a problem.

## Appendix A. GRADE Methodology adapted by UW Health



### GRADE Ranking of Evidence

<b>High</b>	We are confident that the effect in the study reflects the actual effect.
<b>Moderate</b>	We are quite confident that the effect in the study is close to the true effect, but it is also possible it is substantially different.
<b>Low</b>	The true effect may differ significantly from the estimate.
<b>Very Low</b>	The true effect is likely to be substantially different from the estimated effect.

### GRADE Ratings for Recommendations For or Against Practice

<b>Strong</b>	The net benefit of the treatment is clear, patient values and circumstances are unlikely to affect the decision.
<b>Weak/conditional</b>	Recommendation may be conditional upon patient values and preferences, the resources available, or the setting in which the intervention will be implemented.



## Appendix B. Treatment of Bleeding Associated with Oral Anticoagulants


Anticoagulant	Half-life <sup>8</sup>	Reversal Agent / Bleeding Treatment	Comments	Lab									
<p>In all cases of substantial bleeding supportive strategies by means of discontinuation of anticoagulant, mechanical compression and administration of blood products, fluid resuscitation, hemodynamic and respiratory support are required. In addition maintain normal body temperature, blood pH and electrolyte balance to facilitate coagulation. (See <a href="#">UW Health Indications for Blood Product Transfusion – Adult – Inpatient/Ambulatory Clinical Practice Guideline</a>)</p>													
<a href="#">Apixaban</a>	12 h	<ul style="list-style-type: none"> <li>If ingestion within 3 hours, consider activated charcoal 50 g</li> <li>Plasma is not indicated unless the patient has received at least 4 units of PRBCs and the INR is prolonged (i.e., hemodilution).</li> <li>PCC 25-50 units/kg (maximum 2500 - 5000 units) might be considered for life-threatening conditions or urgent surgery.</li> </ul>	-Administer PCC at a maximum rate of 200 units/min	NA									
<a href="#">Edoxaban</a>	10-14 h												
<a href="#">Rivaroxaban</a>	5-9 h												
<a href="#">Dabigatran</a>	12-17 h	<ul style="list-style-type: none"> <li>If ingestion within 3 hours, consider activated charcoal 50 g Po or per enteral tube</li> <li>Idarucizumab 5 grams IV if dabigatran was taken within the previous 12 hours OR TT is <math>\geq 25</math> sec<math>\ddagger</math></li> </ul>	Hemodialysis removes approximately 60% within 2 h										
<a href="#">Warfarin</a>	36-42 h	Severity of Bleeding	Treatment Measures	-High doses of phytonadione can cause difficulty in anticoagulating patients after resolution of the bleeding episode  -Administer phytonadione IV over 20-30 minutes, faster administration can result in anaphylaxis  -Administer PCC at a maximum rate of 200 units/min  -PCC can cause hypersensitivity reactions	INR								
		No bleeding or minor bleeding	<ul style="list-style-type: none"> <li>INR 4.5-9.9 omit 1-2 doses</li> <li>INR &gt;9.9 – omit 1-2 doses, phytonadione 1-2.5 mg PO/IV</li> </ul>										
		Major, Life threatening bleed, emergency surgery or major procedure	<ul style="list-style-type: none"> <li>Phytonadione 5-10 mg IV with the dose dependent upon risk thromboembolism and severity of bleed</li> <li>PCC based on INR and weight</li> </ul> <table border="1" style="margin-left: 20px;"> <thead> <tr> <th style="text-align: center;">Pre-treatment INR</th> <th style="text-align: center;">Dose of PCC</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;"><math>\leq 6.0</math></td> <td style="text-align: center;">1000 units</td> </tr> <tr> <td style="text-align: center;"><math>\geq 6.1</math></td> <td style="text-align: center;">2000 units</td> </tr> <tr> <td style="text-align: center;">Any INR with CNS bleed</td> <td style="text-align: center;">2000 units</td> </tr> </tbody> </table>			Pre-treatment INR	Dose of PCC	$\leq 6.0$	1000 units	$\geq 6.1$	2000 units	Any INR with CNS bleed	2000 units
		Pre-treatment INR	Dose of PCC										
$\leq 6.0$	1000 units												
$\geq 6.1$	2000 units												
Any INR with CNS bleed	2000 units												
May repeat with 500 units if INR goal or clinical outcome not achieved Give each agent as soon as it is available													

NA – not applicable; PCC – prothrombin complex concentrate

### Appendix C. Treatment of Bleeding Associated with Parenteral Anticoagulants

Anticoagulant	Usual Half-life	Reversal Agent / Bleeding Treatment	Comments	Lab Monitoring	
In all cases of substantial bleeding supportive strategies by means of discontinuation of anticoagulant, mechanical compression and administration of blood products, fluid resuscitation, hemodynamic and respiratory support are required. In addition maintain normal body temperature, blood pH and electrolyte balance to facilitate coagulation. (See					
<b>Argatroban IV</b>	45 min	General supportive measures		aPTT	
<b>Bivalirudin IV</b>	25 min	General supportive measures		aPTT	
<b>Fondaparinux Subcutaneous</b>	17-21 h	General supportive measures		anti-Xa	
<b>Heparin IV</b>	1 - 1.5 h	<ul style="list-style-type: none"> <li>Protamine 1 mg per100 units of heparin administered within the last 2 hours. Maximum dose 50 mg.</li> <li>Consider monitoring trends in anti-Xa or ACT to determine requirement for subsequent protamine dosing</li> </ul>	<ul style="list-style-type: none"> <li>- high doses of protamine can enhance anticoagulation</li> <li>-administer protamine over 10 minutes</li> <li>-protamine can cause anaphylaxis</li> </ul>	anti-Xa ACT	
<b>LMWH Subcutaneous</b> (e.g., enoxaparin, dalteparin)	3 -5 h	Time of Last Dose	Treatment Measures	- If patient has renal insufficiency consider wider timeline for administering protamine	anti-Xa
		Within last 8 h	Protamine 1 mg/100 anti-Xa units (maximum 50 mg)		
			If bleeding continues, repeat protamine 0.5 mg/100 anti-Xa units (maximum 25 mg)		
		8 – 12 h ago	Protamine 0.5 mg/ 100 units anti-Xa units (maximum 50mg)		
Dose > 12 h ago	Protamine may not be necessary				

## Appendix D – Treatment of Life Threatening Bleeding Associated with Anticoagulants



## Appendix E – Administration Rate of Intravenous Procoagulant Agents

(See also Intravenous Administration Guideline – Adult – Inpatient/Ambulatory Clinical Practice Guideline)

Medication	Rate of Administration
Desmopressin	Over 20 – 30 minutes
Factor 7A	Over 2 minutes
Idarucizumab	Over 10 - 20 minutes
Phytonadione	Over 20 – 30 minutes
Protamine	10 mg over 1 – 3minutes, 50 mg over 10 minutes minimum
Prothrombin Complex Concentrate (PCC)	100 units/minute, maximum 200 units/minute

## Appendix F – Literature Summary for Low Fixed Dose PCC

Reference	Patient Population	PCC Type	N	PCC Dose	INR Goal	INR Outcome Achieved	Comments
Abdoellakhan R, 2017	Warfarin reversal for ICH	4 Factor (Cofact)	N = 28 N = 25	Fixed dose 1000 IU Weight based (WB)	≤1.5	68% FD 96% WB	Mean dose WB: 1750 IU Median INR: 3.1 (WB) and 3.3 (FD) Per study FD may have been too low for ICH bleeding
Kantorovich A, 2015	Heart transplant surgery	3 Factor	N = 16	INR ≤ 3.5: 10 units/kg INR > 3.5: 20 units/kg	< 1.7	75%	Median INR 2.46 (2.2-2.9) Average weight 80.8 kg Higher percentage of patients received the 20 units/kg dose
Klein L, 2015	Warfarin reversal for any reason	4 Factor (Kcentra)	N = 39	Fixed dose 1500 IU	< 2.0 ≤1.5	92.3% 71.8%	Average weight 79.5 kg Median INR: 3.3 (2.5-4.0) <i>Second dose needed in 1 patient</i>
Quick JA, 2015	Acute care surgery	3 Factor	N = 41	15 units/kg	< 1.5	78%	Median INR 2.52 Higher percentage of failure seen with INR > 4.3
Hirri HM, 2014	Warfarin reversal for any reason	4 Factor (Octaplex)	N = 67	CNS bleeds 2000 IU Other bleeds 1500 IU Non-bleeding 1000 IU	≤1.5	83.6%	Higher percentage of failure seen with INR > 6 None needed a second dose
Varga C, 2013	Warfarin reversal for any reason	4 Factor (Octaplex)	N = 103	1000 IU	≤1.5 < 2.0	48.5% 92.2%	Median INR: 2.8 (1.4 – 24) Higher INR may require higher PCC dosing (not clear in study the definition of higher INR)
Khorsand N, 2012	Warfarin reversal for any reason (except ICH)	4 Factor	N = 101 N = 139	Fixed dose 1040 IU Weight based (WB)	< 2.0	92% FD 95% WB	Median INR FD 5.1 and WB 5.9 Higher percentage of failure seen with INR > 7.5
Khorsand N, 2011	Warfarin reversal for any reason (except ICH)	4 Factor (Cofact)	N = 35 N = 32	1040 IU for bleeding 520 IU for procedure reversal	<1.5 <2.0 (if epidural use < 1.8)	70% 81%	Median INR: 4.7 (2.0 - > 9.0) Higher percentage of failure seen with INR > 5 Clinical outcomes achieved 91% and 94%

## References

1. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. *J Thromb Haemost.* 2010;8(1):202-204.
2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e44S-88S.
3. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. *Circulation.* 2007;115(21):2689-2696.
4. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. *Chest.* 2001;119(1 Suppl):108S-121S.
5. Mannucci PM, Levi M. Prevention and treatment of major blood loss. *N Engl J Med.* 2007;356(22):2301-2311.
6. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest.* 2008;133(6 Suppl):257S-298S.
7. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. *Arch Intern Med.* 2007;167(3):239-245.
8. Vink R, Kraaijenhagen RA, Hutten BA, et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. *J Am Coll Cardiol.* 2003;42(12):2042-2048.
9. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *Am J Med.* 1998;105(2):91-99.
10. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. *Mayo Clin Proc.* 1995;70(8):725-733.
11. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. *Lancet.* 1996;348(9025):423-428.
12. Palareti G, Legnani C, Guazzaloca G, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. *Br J Haematol.* 2005;129(1):72-78.
13. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding: A Randomized, Plasma-Controlled, Phase IIIb Study. *Circulation.* 2013;128(11):1234-1243.
14. Goldstein JN, Refaai MA, Milling TJ, Jr., et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. *Lancet.* 2015;385(9982):2077-2087.
15. Beynon C, Potzy A, Jungk C, Unterberg AW, Sakowitz OW. Rapid Anticoagulation Reversal With Prothrombin Complex Concentrate Before Emergency Brain Tumor Surgery. *J Neurosurg Anesthesiol.* 2015;27(3):246-251.
16. Abdoellakhan R, Miah I, Khorsand N, Meijer K, Jellema K. Fixed versus variable dosing of prothrombin complex concentrate in vitamin K antagonist-related intracranial hemorrhage: a retrospective analysis. *Neurocrit Care.* 2017; 26:64-69.
17. Kantorovich A, Fink JM, Militello MA, et al. Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant. *Ann Pharmacother.* 2015; 49(8): 876-82.
18. Klein L, Peters J, Miner J, Gorlin J. Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal. *Am J Emerg Med.* 2015; 33(9):1213-18.
19. Quick JA, Meyer JM, Coughenour JP, Barnes SL. Less is more: low-dose prothrombin complex concentrate effective in acute care surgery patients. *Am Surg.* 2015; 81(6): 646-50.
20. Hirri HM, Green PJ. Audit of warfarin reversal using a new Octaplex reduced dose protocol. *Transfus Apher Sci.* 2014; 51(2): 141-5.
21. Varga C, Al-Touri S, Papadoukakis S, et al. The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin. *Transfusion.* 2013; 53: 1451-81.
22. Khorsand N, Veeger NJ, van Hest RM et al. An observational, prospective, two-cohort comparison of a fixed versus variable dosing strategy of prothrombin complex concentrate to counteract vitamin K antagonists in 240 bleeding emergencies. *Haematologica.* 2012; 97(10): 1501-6.
23. Khorsand N, Veeger NJ, Muller M, et al. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy. *Transfus Med.* 2011; 21: 116-23.
24. Kcentra [package insert]. CSL Behring LLC., Kankakee, IL; April 2013.  
[http://www.kcentra.com/docs/Kcentra\\_Prescribing\\_Information.pdf](http://www.kcentra.com/docs/Kcentra_Prescribing_Information.pdf).

25. Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. *Lancet*. 2015;385(9982):2077-2087.
26. Frontera JA, Gordon E, Zach V, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. *Neurocrit Care*. 2014;21(3):397-406.
27. Nuckles KB, Pratt JH, Cameron CM, Ingemi AI. Case series of four-factor prothrombin complex concentrate for warfarin reversal before heart transplantation. *Transplant Proc*. 2015;47(3):841-843.
28. Hickey M, Gatien M, Taljaard M, Aujnarain A, Giulivi A, Perry JJ. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. *Circulation*. 2013;128(4):360-364.
29. Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. *Thromb Haemost*. 2016;116(5):879-890.
30. Popovsky MA. Transfusion-related acute lung injury: incidence, pathogenesis and the role of multicomponent apheresis in its prevention. *Transfus Med Hemother*. 2008; 35(2):76-79.
31. Tsu LV, Dienes JE, Dager WE. Vitamin K dosing to reverse warfarin based on INR, route of administration and home warfarin dose in the acute/critical care setting. *Ann Pharmacother*. 2012; 46(12): 1617-1626.
32. Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. *Hematology Am Soc Hematol Educ Program*. 2008:36-38.
33. Morgenstern LB, Hemphill JC, 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2010;41(9):2108-2129.
34. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. *Blood*. 2010;116(5):693-701
35. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361(12):1139-1151.
36. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. *Thromb Haemost*. 2010;103(6):1116-1127
37. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. *Blood*. 2013;121(18):3554-3562.
38. Pollack CV, Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. *N Engl J Med*. 2015;373(6):511-520.
39. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. *Lancet*. 2015;386(9994):680-690
40. Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011.
41. Thomas G, Evelyne E. Antifibrinolytic in subarachnoid hemorrhage. *Neurosurgery*. 2011;69(2):E505-507.
42. Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. *J Thromb Haemost*. 2011;9(9):1705-1712.
43. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. *Circulation*. 2011;124(14):1573-1579
44. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. *Thromb Haemost*. 2012;108(2)
45. Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK. Reversibility of apixaban anticoagulation with a four-factor prothrombin complex concentrate in health volunteers. *Clin Transl Sci*. 2016; 9:176-80.
46. Song Y, Wang Z, Perlstein I, Wang J, LaCreta F, Frost RJ. Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in health subjects: a randomized 3-period crossover study. *J Thromb Haemost* 2017; doi: 10.1111/jth.13815
47. Durie R, Kohute M, Fernandez C, Knight M. Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban. *J Clin Pharm Ther*. 2016; 41(1): 92-3.
48. Grandhi R, Newman WC, Zhang X, et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. *World Neurosurg*. 2015; 84(6): 1956-61.
49. Ammar M, Agren A, Holmstrom M, et al. Management of rivaroxaban or apixaban associated major bleeding with prothrombin complex concentrates: a cohort study. *Blood*. 2017; doi: 10.1182/blood-2017-05-782060.

50. Patanwala AE, Acquisto NM, Erstad BL. Prothrombin complex concentrate for critical bleeding. *Ann Pharmacother*. 2011;45(7-8):990-999.
51. Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. *Circulation*. 2015;131(1):82-90.
52. Kauffmann S, Chabanne R, Coste A, et al. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation. *A A Case Rep*. 2015;4(11):151-154.
53. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e24S-43S
54. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. *Br J Haematol*. 2002;116(1):178-186
55. Lindblad B, Borgstrom A, Wakefield TW, Whitehouse WM, Jr., Stanley JC. Protamine reversal of anticoagulation achieved with a low molecular weight heparin. The effects on eicosanoids, clotting and complement factors. *Thromb Res*. 1987;48(1):31-40.
56. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. *Haemostasis*. 1986;16(2):139-146
57. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines *Chest*. 2012;141; 2 suppl:e24S-e43s.
58. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. *Arch Intern Med*. 2003;163(20):2469-2473.
59. Bordes J, Asencio Y, Kenane N, Fesselet J, Meaudre E, Goutorbe P. Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux. *Br J Anaesth*. 2008;101(4):575-576
60. Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. *Cleve Clin J Med*. 2013;80(7):443-451.
61. Cherfan A, Arabi Y, Al Askar A, Al Shimemeri A. Recombinant activated factor VII treatment of retroperitoneal hematoma in a patient with renal failure receiving enoxaparin and clopidogrel. *Pharmacotherapy*. 2007;27(5):755-759.
62. Monte AA, Bodmer M, Schaeffer TH. Low-molecular-weight heparin overdose: management by observation. *Ann Pharmacother*. 2010;44(11):1836-1839.
63. Firozvi K, Deveras RA, Kessler CM. Reversal of low-molecular-weight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. *Am J Hematol*. 2006;81(8):582-589
64. Argatroban [package insert]. Charlottesville, VA: Aftron Scientific Corp; 2012
65. Angiomax [package insert]. The Medicines Company, Parsippany, NJ. May 2013. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2013/020873s029lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020873s029lbl.pdf).
66. Malherbe S, Tsui BC, Stobart K, Koller J. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. *Anesthesiology*. 2004;100(2):443-445
67. Lowe MP, Collins J, Yehia M, Eaddy N. Reversal of dabigatran with haemodialysis in a patient requiring decompression for cord compression from an epidural abscess. *Nephrology (Carlton)*. 2013;18(8):580-582.
68. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. *Blood Coagul Fibrinolysis*. 2007;18(6):547-553.
69. Le Sache F, Le Bonniec B, Gaussem P, et al. Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit. *Br J Anaesth*. 2012;108(4):586-593.
70. Arixtra [package insert]. Research Triangle Park, NC: GlaxoSmithKline. 2010
71. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. *Circulation*. 2002;106(20):2550-2554
72. Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage. *Neurocrit Care*. 2016; 24:6-46.
73. Sinzinger H, Fitscha P, Peskar BA. Platelet half-life, plasma thromboxane-B2 and circulating endothelial-cells in peripheral vascular-disease. *Angiology*. 1986;37:112-8.
74. Grossman CM, Macewan AM, Dilley J. The half-life of human platelet phosphatide. *Nature*. 1960;188:950-1.
75. Ferraris VA, Saha SP, Oestreich JH, et al. 2012 Update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and non-cardiac operations. *Ann Thorac Surg*. 2012; 94:1761-81.

76. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. *Am J Med.* 1998; 104(3A): 2S-8S.
77. Li X, Sun Z, Zhao W, et al. Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage. *J Neurosurg.* 2013;118:94–103.
78. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. *Lancet.* 2016; 387(10038):2605-13.
79. Gratz I, Koehler J, Olsen D et al (1992) The effect of desmopressin acetate on postoperative hemorrhage in patients receiving aspirin therapy before coronary artery bypass operations. *J Thorac Cardiovasc Surg* 104:1417–1422
80. Flordal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. *Br J Surg.* 1993;80:723–4.
81. Kapapa T, Rohrer S, Struve S, et al. Desmopressin acetate in intracranial haemorrhage. *Neurol Res Int.* 2014;2014:298767.
82. Wijeyeratne YD, Heptinstall S. Antiplatelet therapy: ADP receptor antagonists. *Br J Clin Pharmacol.* 2011; 72(4): 647-57.
83. Naidech AM, Liebling SM, Rosenberg NF, et al. Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. *Neurocrit Care.* 2012;16:82–7.
84. Washington CW, Schuerer DJ, Grubb RL Jr. Platelet transfusion: an unnecessary risk for mild traumatic brain injury patients on antiplatelet therapy. *J Trauma.* 2011;71:358–63.
85. Joseph B, Pandit V, Sadoun M, et al. A prospective evaluation of platelet function in patients on antiplatelet therapy with traumatic intracranial hemorrhage. *J Trauma Acute Care.* 2013;75:990–4.
86. Ducruet AF, Hickman ZL, Zacharia BE, et al. Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. *Neurol Res.*2010;32:706–10.
87. Ranucci M, Nano G, Pazzaglia A, Bianchi P, Casana R, Tealdi DG. Platelet mapping and desmopressin reversal of platelet inhibition during emergency carotid endarterectomy. *J Cardiothorac Vasc Anesth.* 2007; 21(6): 851-4.
88. Leithauser B, Zielske D, Seyfert UT, Jung F. Effects of desmopressin on platelet membrane glycoproteins and platelet aggregation in volunteers on clopidogrel. *Clin Hemorheol Microcirc.* 2008;39:293–302.
89. Teng R, Mitchell PD, Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. *J Clin Pharm Ther.* 2014;39:186–91
90. Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors basic and clinic aspects. *Arterioscler Thromb Vasc Biol.* 1999; 19:2835-40.